Cargando…
Using a decline in serum hCG between days 0–4 to predict ectopic pregnancy treatment success after single-dose methotrexate: a retrospective cohort study
BACKGROUND: The current measure of treatment efficacy of single-dose methotrexate for ectopic pregnancy, is a fall in serum hCG of ≥15% between days 4–7 of treatment, which has a positive predictive value of 93% for treatment success. Two small studies have proposed a fall in serum hCG between days...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3577505/ https://www.ncbi.nlm.nih.gov/pubmed/23369098 http://dx.doi.org/10.1186/1471-2393-13-30 |
_version_ | 1782259927169892352 |
---|---|
author | Skubisz, Monika Dutton, Philip Duncan, William Colin Horne, Andrew W Tong, Stephen |
author_facet | Skubisz, Monika Dutton, Philip Duncan, William Colin Horne, Andrew W Tong, Stephen |
author_sort | Skubisz, Monika |
collection | PubMed |
description | BACKGROUND: The current measure of treatment efficacy of single-dose methotrexate for ectopic pregnancy, is a fall in serum hCG of ≥15% between days 4–7 of treatment, which has a positive predictive value of 93% for treatment success. Two small studies have proposed a fall in serum hCG between days 0–4 after treatment confers similar, earlier prognostic information, with positive predictive values of 100% and 88% for treatment success. We sought to validate this in a large, independent cohort because of the potentially significant clinical implications. METHODS: We conducted a retrospective study of women (n=206) treated with single-dose methotrexate for ectopic pregnancy (pre-treatment serum hCG levels ≤3000 IU/L) at Scottish hospitals between 2006–2011. Women were divided into two cohorts based on whether their serum hCG levels rose or fell between days 0–4 after methotrexate. Treatment outcomes of women in each cohort were compared, and the test performance characteristics calculated. This methodology was repeated for the current measure (≥15% fall in serum hCG between days 4–7 of treatment) and an alternate early measure (<20% fall in serum hCG between days 0–4 of treatment), and all three measures were compared for their ability to predict medical treatment success. RESULTS: In our cohort, the positive predictive value of the current clinical measure was 89% (95% CI 84-94%) (121/136). A falling serum hCG between days 0–4 predicted treatment success in 85% (95% CI 79-92%) of cases (94/110) and a <20% fall in serum hCG between days 0–4 predicted treatment success in 94% (95% CI 88-100%) of cases (59/63). There was no significant difference in the ability of these tests to predict medical treatment success. CONCLUSIONS: We have verified that a decline in serum hCG between days 0–4 after methotrexate treatment for ectopic pregnancies, with pre-treatment serum hCG levels ≤3000 IU/L, provides an early indication of likelihood of treatment success, and performs just as well as the existing measure, which only provides prognostic information on day 7. |
format | Online Article Text |
id | pubmed-3577505 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35775052013-02-21 Using a decline in serum hCG between days 0–4 to predict ectopic pregnancy treatment success after single-dose methotrexate: a retrospective cohort study Skubisz, Monika Dutton, Philip Duncan, William Colin Horne, Andrew W Tong, Stephen BMC Pregnancy Childbirth Research Article BACKGROUND: The current measure of treatment efficacy of single-dose methotrexate for ectopic pregnancy, is a fall in serum hCG of ≥15% between days 4–7 of treatment, which has a positive predictive value of 93% for treatment success. Two small studies have proposed a fall in serum hCG between days 0–4 after treatment confers similar, earlier prognostic information, with positive predictive values of 100% and 88% for treatment success. We sought to validate this in a large, independent cohort because of the potentially significant clinical implications. METHODS: We conducted a retrospective study of women (n=206) treated with single-dose methotrexate for ectopic pregnancy (pre-treatment serum hCG levels ≤3000 IU/L) at Scottish hospitals between 2006–2011. Women were divided into two cohorts based on whether their serum hCG levels rose or fell between days 0–4 after methotrexate. Treatment outcomes of women in each cohort were compared, and the test performance characteristics calculated. This methodology was repeated for the current measure (≥15% fall in serum hCG between days 4–7 of treatment) and an alternate early measure (<20% fall in serum hCG between days 0–4 of treatment), and all three measures were compared for their ability to predict medical treatment success. RESULTS: In our cohort, the positive predictive value of the current clinical measure was 89% (95% CI 84-94%) (121/136). A falling serum hCG between days 0–4 predicted treatment success in 85% (95% CI 79-92%) of cases (94/110) and a <20% fall in serum hCG between days 0–4 predicted treatment success in 94% (95% CI 88-100%) of cases (59/63). There was no significant difference in the ability of these tests to predict medical treatment success. CONCLUSIONS: We have verified that a decline in serum hCG between days 0–4 after methotrexate treatment for ectopic pregnancies, with pre-treatment serum hCG levels ≤3000 IU/L, provides an early indication of likelihood of treatment success, and performs just as well as the existing measure, which only provides prognostic information on day 7. BioMed Central 2013-02-01 /pmc/articles/PMC3577505/ /pubmed/23369098 http://dx.doi.org/10.1186/1471-2393-13-30 Text en Copyright ©2013 Skubisz et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Skubisz, Monika Dutton, Philip Duncan, William Colin Horne, Andrew W Tong, Stephen Using a decline in serum hCG between days 0–4 to predict ectopic pregnancy treatment success after single-dose methotrexate: a retrospective cohort study |
title | Using a decline in serum hCG between days 0–4 to predict ectopic pregnancy treatment success after single-dose methotrexate: a retrospective cohort study |
title_full | Using a decline in serum hCG between days 0–4 to predict ectopic pregnancy treatment success after single-dose methotrexate: a retrospective cohort study |
title_fullStr | Using a decline in serum hCG between days 0–4 to predict ectopic pregnancy treatment success after single-dose methotrexate: a retrospective cohort study |
title_full_unstemmed | Using a decline in serum hCG between days 0–4 to predict ectopic pregnancy treatment success after single-dose methotrexate: a retrospective cohort study |
title_short | Using a decline in serum hCG between days 0–4 to predict ectopic pregnancy treatment success after single-dose methotrexate: a retrospective cohort study |
title_sort | using a decline in serum hcg between days 0–4 to predict ectopic pregnancy treatment success after single-dose methotrexate: a retrospective cohort study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3577505/ https://www.ncbi.nlm.nih.gov/pubmed/23369098 http://dx.doi.org/10.1186/1471-2393-13-30 |
work_keys_str_mv | AT skubiszmonika usingadeclineinserumhcgbetweendays04topredictectopicpregnancytreatmentsuccessaftersingledosemethotrexatearetrospectivecohortstudy AT duttonphilip usingadeclineinserumhcgbetweendays04topredictectopicpregnancytreatmentsuccessaftersingledosemethotrexatearetrospectivecohortstudy AT duncanwilliamcolin usingadeclineinserumhcgbetweendays04topredictectopicpregnancytreatmentsuccessaftersingledosemethotrexatearetrospectivecohortstudy AT horneandreww usingadeclineinserumhcgbetweendays04topredictectopicpregnancytreatmentsuccessaftersingledosemethotrexatearetrospectivecohortstudy AT tongstephen usingadeclineinserumhcgbetweendays04topredictectopicpregnancytreatmentsuccessaftersingledosemethotrexatearetrospectivecohortstudy |